A Randomized Phase I Study With a Safety Lead-In to Assess the Antitumor Efficacy of the MEK Inhibitor Trametinib Alone or in Combination With GSK2141795, an AKT Inhibitor, in Patients With Recurrent or Persistent Endometrial Cancer NCT #01935973

Trial Profile

A Randomized Phase I Study With a Safety Lead-In to Assess the Antitumor Efficacy of the MEK Inhibitor Trametinib Alone or in Combination With GSK2141795, an AKT Inhibitor, in Patients With Recurrent or Persistent Endometrial Cancer NCT #01935973

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Sep 2017

At a glance

  • Drugs Trametinib (Primary) ; Uprosertib (Primary)
  • Indications Adenocarcinoma; Endometrial cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 10 Aug 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
    • 27 Mar 2014 New source identified and integrated (M D Anderson Cancer Center- GOG0229O)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top